This is where developments land: a platform we review changing its price, panel, or regulatory standing, or new research in a category we publish. Each briefing summarizes what happened in a sentence or two, then spends most of its length on the part a wire story leaves out: what the development does and does not change for someone choosing between these platforms.
Every figure on these pages is copied from a source we fetched and read, linked by name. We do not rewrite evergreen review pages here; those live under their category hubs. Ordering is by date, newest first, and carries no ranking.
Keto cut liver fat 67% at the same weight loss as two other diets
A 55-person randomized trial at Washington University supplied every meal for five months. Liver fat fell 67% on a ketogenic diet against 45% on Mediterranean and plant-forward diets, with weight loss matched at about 10%.
A 2,501-man trial improved cholesterol without reducing heart attacks
RADICAL PC 2 randomized men with prostate cancer to a cardiology referral or usual care. Statin use rose from 40% to 63% and cholesterol fell, and cardiovascular events did not differ over nearly six years.
A 17,024-man analysis links ultra-processed food to prostate cancer — in data that cannot show which came first
An FAU-led analysis of NHANES 2003–2023 reports 24% to 31% higher prostate cancer risk in men eating more ultra-processed food. The design is cross-sectional, and no confidence intervals were published.
A 183,450-woman cohort links HRT use to a lower rate of dementia
In the UK Biobank, postmenopausal women who used hormone replacement therapy for a year or more had a 10% lower rate of dementia. The subgroup results and the absolute numbers behind that figure.
An Alzheimer's sleep study measured brain waves consumer trackers do not report
A 60-person Neurology study linked NREM sleep spindles and slow oscillations to CSF orexin and to 36-month cognitive outcomes in diagnosed Alzheimer's disease. Why a deep sleep score is not the same measurement.
A Stanford analysis ties LDL increases on low-carb diets to a genetic score
A secondary analysis of the DIETFITS trial found that people with a higher polygenic tendency toward high LDL saw larger increases on a low-carb diet. No effect sizes were released, and the abstract is not peer reviewed.
A federal guideline reviewed the body fat measurements and endorsed none of them
The 2025 VA/DoD obesity guideline found insufficient evidence to recommend any particular measure of adiposity for managing clinical outcomes. What that reframes about DEXA scans and visceral fat ratings.
Galleri gets a payer route through a Michigan health plan
Priority Health is enabling Michigan self-insured employer groups to add GRAIL's Galleri test to existing cancer screening coverage. One state, one plan, and the first payer route into a self-pay tier.
An Alzheimer's blood test just got cleared — and the clearance says it is not for screening
The FDA cleared C2N Diagnostics' PrecivityAD2 for adults 40+ who already have signs of cognitive impairment. The indication rules out screening, and the intermediate result band is the number worth reading.
A research team compressed the gut microbiome into one number — here is what it tracked
A Microbial Health Index built from 97 health-associated and 31 disease-associated bacterial variants correlated with diet, fitness and lipids in 893 adults. No accuracy figures were reported.
Function Health takes $450M in growth financing — what it changes for buyers
Function closed $450 million from General Catalyst's Customer Value Fund, described as non-dilutive. Why customer-acquisition capital shows up in the price list rather than the panel.
The cheapest high-evidence screening test is the one almost nobody discusses
University of Cincinnati researchers found just 15% of eligible US adults had discussed lung cancer screening with a doctor, against 70–80% for colonoscopy and mammography.
A 376,511-person cohort quantifies what colorectal screening buys you
In the Stockholm-Gotland program, participating in fecal occult blood screening was associated with a 43% lower rate of colorectal cancer death. What that number is, and what it means for self-pay screening.
A small trial tested fasting windows in type 1 diabetes — carefully
A 32-person randomized trial at UIC found time-restricted eating lowered HbA1c relative to calorie counting, without raising hypoglycemia or ketoacidosis risk. What a pilot of this size does not settle.
WHOOP drops the membership requirement for lab testing — and adds Galleri
WHOOP and Quest made Advanced Labs available without a WHOOP membership and added GRAIL's Galleri multi-cancer test. Why the membership change matters more than the headline.
A tape measure outpredicted epigenetic clocks in a Finnish cohort
In 1,108 middle-aged Finns followed 7–9 years, BMI, waist-to-hip ratio, smoking and alcohol predicted new chronic disease better than the epigenetic clocks tested.
Galleri heads to an FDA advisory panel
The FDA set a September 23, 2026 advisory-committee review of the Galleri multi-cancer blood test. What the meeting does and does not change for a buyer.
InsideTracker adds a source-agnostic blood-data connector
InsideTracker will read blood results from outside labs, PDFs, Apple Health and EMRs across nearly 120 markers. Why it matters for buyers who already have bloodwork.
A research blood test targets bile acids, an overlooked liver marker
University of Toledo researchers report a fast whole-blood test for elevated bile acids, validated in 23 patients. Early-stage, research-only, and what it says about panel breadth.
How these briefings are built
Detection is only a signal. A headline from an aggregator is never enough to publish from, because those links do not resolve to article text. Before a briefing ships, the underlying event is re-grounded in a fetchable primary source: a company's own newsroom, the trade outlet that broke it, an FDA or court record, or the journal paper itself. If no primary source states the claim, the story is dropped rather than written. Prices, doses, lab ranges and study numbers come from that source or an official page, never from a headline.
The Two Kinds of Story That Land Here
Briefings arrive in two streams. Platform news covers what the companies on our review roster did: a funding round, a panel or price change, an FDA action, a lawsuit, a clinical validation of their own test. Those matter because they change the thing a reader is choosing between, and they rarely reach the review pages fast enough on their own.
Science covers new research in a category we already publish. A trial readout, a cohort result, a guideline change, or a safety signal on something readers use. A finding qualifies when it could change what someone does or believes, and a mechanism paper with no human read does not qualify however interesting it is.
Most candidates never become a page. A story gets dropped when no primary source can be found, when the development is already documented on an existing guide, when the real subject falls outside what this site covers, or when a headline turns out to be recycled coverage of something months old. Dropping is the normal outcome, and the volume of it is what keeps the pages that do ship worth reading.
A briefing never rewrites an evergreen page. When a development makes an existing review stale, the correction is handled on that review, and the briefing stays a dated record of what changed and when. That separation keeps a decaying news item from diluting a guide people arrive at through an evergreen question years later.
Related
- Longevity platforms, compared: all on one rubric
- Biomarker guides: what the panels actually measure
- How we review